Full results from the phase 2b LUMA showed that investigational BIIB122/DNL151 did not slow confirmed clinical worsening in early-stage Parkinson's disease compared with placebo.
Phase 3 randomized-withdrawal data in pediatrics indicated relapse in 41.9% continuing ecopipam versus 68.1% on placebo, a 53% relative relapse-risk reduction (HR, 0.50; P = .008). New analyses from ...
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later. An updated ...
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Dravet syndrome treatment ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
Cluster headache care remains hindered by migraine overlap, contributing to diagnostic delay and prolonged unmet need for ...
NeurologyLive Brain Games is a weekly quiz series that goes live every Sunday morning, featuring questions on a variety of ...
Treatment initiation before 90 days correlated with markedly higher independent walking (73.2% vs 36.7%) and fewer ...
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized ...
Tasimelteon advanced sleep onset by 42.5 minutes versus 5.4 minutes with placebo in DSWPD, meeting the primary endpoint with ...
The FDA has approved tavapadon (AbbVie), a once-daily oral selective dopamine D1/D5 receptor partial agonist, for adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results